Compugen
在场
Compugen 是一家在股票代码 CGEN (IL) 下上市的公司。
高管
查看带有其 39 名主要高管的组织结构图
Compugen 搜索最多的简介
- Anat Cohen-Dayag, Director, Employee Representative
- Sanford Zweifach, Director
- Mathias Hukkelhoven, Director
高管在Compugen变化
- David SilbermanDavid Silberman 将于20248月15作为 Chief Financial Officer 加入公司 (新闻发布的2024五月16号).
- Alberto Sessa, Chief Financial Officer, 将于 20248月15 退休 (新闻发布的2024五月16号).
创建提醒
跟踪 Compugen 的高管变动
生物技术
Compugen 拥有 2,332 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- March Biosciences 刚刚宣布为 28 筹款数百万美元。 (公布2024十二月3号).
- Lyell Immunopharma 已收购 ImmPACT Bio (公布2024十一月29号).
- Hopo Therapeutics 刚刚宣布为 226 筹款数百万美元。 (公布2024十一月29号).
生物技术 行业的其他推荐联系人
消息
Compugen 的最新新闻稿
- Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
- Compugen to Participate in Stifel 2024 Healthcare Conference
- Compugen Reports Third Quarter 2024 Results
- Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024
- Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
- Compugen to Present New Clinical Data at SITC 2024
- Compugen to Present at Single Cell Genomics 2024 Conference
- Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024
- Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
- View more press releases Close
关于 Compugen 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Anat Cohen-Dayag 
